CancerTYPE ID® with reflex to NeoTYPE® Cancer Profile

NeoGenomics has partnered with Biotheranostics, Inc., a Hologic Company, to make ordering  CancerTYPE ID easy. CancerTYPE ID is a proprietary molecular cancer classifier used to identify unknown or unclear tumor types and subtypes in patients with metastatic cancer. The test uses quantitative RT-PCR to measure the expression of 92 genes in the patients specimen and classifies the tumor by matching the gene expression profile to a database of more than 2000 known tumor types and subtypes. Using this technology, CancerTYPE ID can identify 50 different tumor types and subtypes, covering >95% of all solid tumors based on incidence. The test reports a main cancer type with the highest probability, as well as a list of tumor types that may be ruled out with 95% confidence.

When ordered through NeoGenomics, classification with CancerTYPE ID is followed by tumor profiling for actionable biomarkers using a NeoGenomics NGS Profile most appropriate for the tumor type identified by Cancer TYPE ID.

CancerTYPE ID may be ordered as a stand-alone test directly from Biotheranostics, Inc., a Hologic Company. Please see http://www.cancertypeid.com. 

CancerTYPE ID is performed, reported, and billed separately by Biotheranostics, Inc., a Hologic Company, an independent CLIA-licensed and CAP-accredited reference laboratory.